Sunday, April 01, 2012 1:12:30 PM
Assuming Congress ratifies the draft guidelines, how quickly could you bring biosimilars to the market?
I am not aware of any requirement that Congress must ratify the FDA's guidelines. I assume this is an erroneous statement by the interviewer. However, the new pathway for biosimliars was enacted as part of Obamacare. If the Supremes declare all of Obamacare unconstitutional, does that mean the FDA will stop working on the accelerated pathway. I hope not, but I also suppose Congress will then have to re-enact the biosimilar provisions before the FDA can make effective its rules to implement the pathway. It's anybody's guess as to when a future Congress might act on broad healthcare legislation. Given potential budget savings, biosimilars legislation might have a chance as stand-alone legislation.
FWIW, the comment period for the Q&As the FDA proposed in February ends on April 16th. I doubt that the FDA would require much time to issue final Q&As after the receipt of comments, but whether it will beat the Obamacare decision (expected at the end of June) is questionable.
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm259797.htm
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
